https://www.selleckchem.com/pr....oducts/fenebrutinib-
ents. This case is the first report of immune checkpoint inhibitors-induced thrombocytopenia that developed nearly 2 months after discontinuation of treatment with nivolumab for metastatic NSCLC. In future clinical practice, patients who have received immune checkpoint inhibitors develop new or unexplained symptom, irrespective of interval post-immunotherapy, immune-related adverse events should be considered. Approach to cancer treatment is dictated by guidelines based on clinical research. New research continuously chang
Like
Comment
Share
